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Summary
Background.  —  Several  studies  have  suggested  that  proton-pump  inhibitors  (PPIs),  mostly
omeprazole,  interact  with  clopidogrel  efﬁcacy  by  inhibiting  the  formation  of  its  active  metabo-
lite via  CYP2C19  inhibition.  Whether  this  occurs  with  all  PPIs  is  a  matter  of  debate.  As
rabeprazole  is  a  less  potent  CYP2C19  inhibitor  than  other  PPIs,  we  studied  the  interaction
between  rabeprazole  and  the  antiplatelet  actions  and  pharmacokinetics  of  clopidogrel.
Aim. —  To  demonstrate  the  non-inferiority  of  rabeprazole  over  placebo  using  change  in  platelet
reactivity index  (PRI;  vasodilator-stimulated  phosphoprotein  [VASP]  assay)  in  a  predeﬁned  pop-
ulation of  good  clopidogrel  responders.  Omeprazole  was  used  as  the  positive  control.
Methods.  —  In  this  randomized  three-period  crossover  study  in  healthy  volunteers,  36  healthy
men received  clopidogrel  (75  mg/day  for  7  days)  with  placebo,  omeprazole  (20  mg/day)  or
rabeprazole  (20  mg/day).  Clopidogrel  antiplatelet  effects  and  disposition  kinetics  were  assessed
on day  7  of  combination  therapy.  Non-inferiority  threshold  was  predeﬁned  as  an  upper  limit  of
the 90%  conﬁdence  interval  for  the  difference  in  change  in  PRI  between  placebo  and  rabeprazole
of <  10%  in  good  clopidogrel  responders.
Results.  —  In  good  clopidogrel  responders  (inhibition  of  VASP  index  >  30%),  the  clopidogrel
antiplatelet  effect  remained  non-inferior  to  placebo  during  rabeprazole  (difference  3.4%  [—1.7;
8.5]) but  not  omeprazole  (difference  7.5%  [2.5;  12.6])  co-administration.  The  AUC0—24 and
Cmax of  active  clopidogrel  metabolite  decreased  with  both  omeprazole  and  rabeprazole,  and
conditions of  bioequivalence  were  not  met,  except  for  AUC0—24 with  rabeprazole.
Conclusions.  —  Rabeprazole  does  not  interact  with  clopidogrel  to  the  same  extent  as  omepra-
zole. However,  under  our  experimental  conditions  and  proton-pump  inhibitor  doses,  there  was
no signiﬁcant  pharmacodynamic  interaction  between  rabeprazole  or  omeprazole  and  clopido-
grel, despite  a  signiﬁcant  decrease  in  the  formation  of  clopidogrel  active  metabolite.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Plusieurs  études,  principalement  menées  avec  l’oméprazole,  ont  suggéré  une
interaction  entre  inhibiteurs  de  la  pompe  à  protons  (IPPs)  et  clopidogrel,  via  l’inhibition  du
CYP2C19 impliqué  dans  la  transformation  de  la  pro-drogue  clopidogrel  en  metabolite  actif.
L’importance  de  cette  interaction  avec  les  autres  inhibiteurs  de  pompes  à  protons  est  discutée.
Cette étude  avait  pour  objectif  l’analyse  de  l’interaction  pharmacodynamique  et  pharma-
cocinétique  entre  le  rabéprazole,  un  inhibiteur  plus  faible  du  CYP2C19  que  l’oméprazole,  et  le
clopidogrel.
Objectif. — L’objectif  primaire  était  de  démontrer  la  non-infériorité  du  rabéprazole  par  compa-
raison au  placebo  en  utilisant  l’index  de  réactivité  plaquettaire  (test  VASP)  dans  une  population
de volontaires  sains  bon  répondeurs  au  clopidogrel.  L’oméprazole  a  été  utilisé  comme  contrôle
positif.
Méthodes.  —  Étude  croisée,  randomisée,  en  trois  périodes,  menée  chez  36  hommes  volontaires
sains recevant  du  clopidogrel  (75  mg/jour  pendant  7  jours)  avec  du  placebo,  de  l’oméprazole
(20 mg/jour)  ou  du  rabéprazole  (20  mg/jour).  L’effet  anti-plaquettaire  du  clopidogrel  et  ses
données pharmacocinétiques  ont  été  mesurés  au  7e jour  de  traitement.  Le  seuil  de  non-
infériorité a  été  déﬁni  a  priori  comme  une  limite  supérieure  de  l’intervalle  de  conﬁance  à
90 %  <  10  %  pour  la  différence  entre  la  diminution  de  l’index  de  réactivité  plaquettaire  (test
VASP) entre  le  placebo  et  le  rabéprazole  chez  les  bons  répondeurs  au  clopidogrel.
Résultats.  —  Dans  le  groupe  de  bons  répondeurs  (inhibition  du  VASP  PRI  >  30  %),  l’effet  antipla-
quettaire du  clopidogrel  était  non  inférieur  à  celui  du  placebo  avec  le  rabéprazole  (différence
3,4 %  [—1,7;  8,5])  contrairement  à  l’oméprazole  (différence  7,5  %  [2,5;  12,6]).  Toutefois,
l’AUC0—24 et  la  Cmax du  métabolite  actif  du  clopidogrel  étaient  signiﬁcativement  diminuées
avec l’oméprazole  et  le  rabéprazole  et  les  conditions  de  bioéquivalence  n’étaient  pas  remplies,
excepté pour  l’AUC0—24 avec  le  rabéprazole.
Conclusions.  —  L’interaction  pharmacodynamique  entre  le  rabéprazole  et  le  clopidogrel  n’a  pas
le même  degré  d’intensité  que  celle  entre  l’oméprazole  et  le  clopidogrel.  Cependant,  dans  nos
conditions  expérimentales,  l’interaction  entre  rabéprazole  ou  oméprazole  et  le  clopidogrel
n’était pas  signiﬁcative  malgré  une  inhibition  signiﬁcative  de  la  génération  du  métabolite  actif
du clopidogrel.
© 2013  Elsevier  Masson  SAS.  Tous  droits  réservés.
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[%]  D7H0),  was  used  as  the  primary  study  endpoint.  PRI
(%)  relative  to  day  1  was  also  calculated  for  D7H4.
Platelet  aggregation  was  determined  at  the  samePK/PD  interaction  between  rabeprazole  and  clopidogrel  
Background
Dual  antiplatelet  therapy  with  aspirin  and  clopidogrel
is  associated  with  a  signiﬁcant  reduction  in  cardiovas-
cular  ischemic  events  after  acute  coronary  syndromes
or  percutaneous  coronary  interventions  and  is  recom-
mended  in  guidelines  from  the  USA  [1]  and  Europe  [2].
Clopidogrel  is  an  inactive  prodrug  that  undergoes  two
oxidative  steps  involving  multiple  cytochrome  P-450
(CYP)  enzymes  in  its  bioactivation  to  its  pharmaco-
logically  active  metabolite.  Among  them,  CYP2C19,
a  CYP  enzyme  whose  activity  is  determined  geneti-
cally,  contributes  predominantly  to  this  bioactivation
[3,4]  and  modulates  the  antiplatelet  and  therapeu-
tic  response  to  clopidogrel.  Patients  with  loss  of
function  polymorphism  in  the  CYP2C19  gene  are  less
responsive  to  clopidogrel  [5,6],  although  the  impor-
tance  of  this  phenomenon  remains  controversial  [7—10]
and  may  be  limited  to  the  risk  of  stent  thrombosis
[11].
Proton-pump  inhibitors  (PPIs)  are  recommended  in
patients  treated  with  dual  antiplatelet  therapy  who
are  at  high  risk  of  gastrointestinal  bleeding  [12].
PPIs  are  metabolized  primarily  via  the  CYP2C19  and
CYP3A4  isoenzymes  [13]  and  are  competitive  inhibitors
of  CYP2C19  activity  [14].  However,  the  contribution  of
the  CYP2C19  isoenzyme  to  PPI  biotransformation  and
H.  pylori  eradication  rates  [15]  and  the  potency  of
inhibition  of  CYP2C19  activity  [14]  vary  among  dif-
ferent  PPIs.  CYP2C19  activity  appears  to  affect  the
response  to  omeprazole,  esomeprazole  and  lansoprazole
[16—18]  and  to  be  inhibited  by  these  PPIs  [14,18].  This
does  not  seem  to  be  the  case,  at  least  not  to  the
same  extent,  with  pantoprazole  [14,19]  and  rabeprazole
[14,20].
Concerns  about  PPI  and  clopidogrel  interaction  were
raised  when  omeprazole  was  found  to  inhibit  the
antiplatelet  effect  of  clopidogrel  in  an  in  vivo  study  of
124  patients  undergoing  elective  coronary  stent  implanta-
tion  [21].  Several  studies  have  suggested  that  omeprazole
interacts  with  clopidogrel  efﬁcacy  by  inhibiting  the  forma-
tion  of  its  active  metabolite  via  CYP2C19  inhibition  [22,23].
Whether  this  occurs  with  all  PPIs  or  is  even  of  signiﬁcant
amplitude  with  omeprazole  remains  a  matter  of  debate
[9,24—29].  However,  it  was  recently  demonstrated  that  gen-
eration  of  clopidogrel  active  metabolite  and  inhibition  of
platelet  function  are  reduced  less  by  the  co-administration
of  dexlansoprazole  or  lansoprazole  with  clopidogrel  than
by  the  co-administration  of  esomeprazole  or  omeprazole
[30].
As  rabeprazole  is  a  less  potent  CYP2C19  inhibitor
than  other  PPIs  [14],  we  performed  a  pharmacodynamic
antiplatelet  activity  study  of  the  interaction  between
standard  recommended  repeated  doses  of  rabeprazole
and  clopidogrel  in  CYP2C19-genotyped  healthy  male
subjects.  Omeprazole  and  placebo  were  used  as  con-
trols.  Our  primary  objective  was  to  demonstrate  non-
inferiority  of  rabeprazole  over  placebo  using  the  change
in  platelet  reactivity  index  (PRI%)  in  good  clopi-
dogrel  responders  as  derived  from  the  vasodilator-
stimulated  phosphoprotein  (VASP)  assay  as  the  primary
endpoint. t663
ethods
tudy design
his  was  a  prospective,  placebo-  and  active-controlled,
pen-label,  blinded-evaluation,  randomized,  three-way
rossover  study.  The  study  assessed  the  inﬂuence  of  rabepra-
ole  (20  mg/day  for  7  days)  and  omeprazole  (20  mg/day  for
 days)  on  the  antiplatelet  effects  and  pharmacokinetics  of
lopidogrel  (75  mg/day  for  7  days)  in  36  CYP2C19-genotyped
on-smoking  healthy  Caucasian  male  subjects  with  nor-
al  basal  platelet  aggregation  testing  (>  50%  aggregation  to
 g/mL  collagen,  1—2  mmol/L  arachidonic  acid  and  10  M
denosine  diphosphate  [ADP]),  platelet  count,  complete
lood  count  and  prothrombin  time.  Subjects  gave  written
nformed  consent  to  participate  and  to  have  CYP2C19  geno-
yping  (but  were  not  selected  on  the  basis  of  their  genotype)
nd  the  protocol  was  approved  by  the  Committee  for  Pro-
ection  of  Human  Subjects  Île-de-France  II  and  the  French
edicine  Agency.
Subjects  were  randomized  based  on  a  Latin  square  design
o  receive  clopidogrel  75  mg/day  in  the  morning  in  the  fast-
ng  state  for  7  days  during  three  study  periods  separated  by  a
rug-free  period  of  2—3  weeks,  together  with  placebo,  20  mg
f  rabeprazole  or  20  mg  of  omeprazole,  given  at  the  same
ime  as  clopidogrel.  Platelet  function  evaluation  (pharma-
odynamics)  was  performed  on  day  1  before  dosing  (D1H0)
nd  on  day  7  before  and  4  hours  after  the  last  intake  of  study
rugs  (D7H0  and  D7H4,  respectively).  The  pharmacokinetics
f  clopidogrel,  its  inactive  carboxylic  acid  metabolite  and
he  active  metabolite  were  determined  from  blood  samples
aken  before  (H0)  and  at  various  times  after  administra-
ion  of  the  last  dose  of  clopidogrel  with  the  concomitant
rug  (either  placebo  or  PPI).  Additional  blood  samples
or  determination  of  omeprazole,  5-hydroxyomeprazole,
abeprazole  and  rabeprazole  thioether  plasma  concentra-
ions  were  taken  3  and  4  hours  postdose  on  day  7  to  conﬁrm
roper  exposure  to  PPIs.
harmacodynamic evaluations
he  primary  test  to  assess  platelet  function  was  based  on  the
ASP  phosphorylation  level  measured  in  whole  blood  using  a
ow  cytometric  assay  (Platelet  VASP®; Diagnostica  Stago,
iocytex,  Asnières,  France)  and  a  FACScan  ﬂow  cytome-
er  (Becton  Dickinson,  Le  Pont  de  Claix,  France).  Results
ere  expressed  as  platelet  reactivity  index  (PRI%),  calcu-
ated  from  the  mean  ﬂuorescence  intensity  (MFI)  of  samples
ncubated  with  prostaglandin  E1  (PGE1)  alone  or  with  both
GE1  and  ADP  simultaneously,  using  the  following  formula:
MFIPGE1—MFIPGE1+ADP/MFIPGE1)  ×  100,  as  previously  described
3]. This  test  —  also  referred  to  as  the  VASP  index  —  specif-
cally  assesses  the  activity  of  the  P2Y12  receptor  [31]  (the
arget  of  clopidogrel  antiplatelet  action),  and  is  widely  used
or  monitoring  the  responsiveness  to  clopidogrel  [32,33].
he  percentage  change  in  PRI  on  study  day  7  just  before  the
ast  administration  of  study  drugs  relative  to  baseline,  i.e.
rior  to  drug  administrations  (percentage  change  in  PRIime  points  as  those  used  for  VASP  phosphorylation  level
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ssessments,  with  ADP-induced  platelet  optical  aggregom-
try  (Biopool,  Ventura,  CA,  USA;  ADP  10  and  20  M)  using
latelet-rich  plasma  adjusted  to  250  ×  109/L.  Inhibition  of
latelet  aggregation  (IPA%)  induced  by  ADP  was  calcu-
ated  as:  (MPA[day  1]  —  MPA[day  7]/MPA[day  1]  ×  100),  where
PA  is  the  maximal  platelet  aggregation  induced  by  ADP.
latelet  aggregation  tests  were  performed  on  a  TA-8  V  opti-
al  platelet  aggregometer  (Soderel  Medical,  Heillecourt,
rance)  within  3  hours  of  sampling  in  all  subjects.
Pharmacodynamic  evaluations  were  performed  blind  to
he  study  period  and  the  CYP2C19  genotype.
harmacokinetic evaluations
lood  samples  for  the  clopidogrel  assay  were  col-
ected  in  6  mL  ethylenediaminetetraacetic  acid  (EDTA)
ials  stored  at  4 ◦C,  to  which  38  L  of  2-bromo-
′-methoxyacetophenone  (500  mM  in  acetonitrile)
ere  added  within  30  seconds  of  sampling  to  sta-
ilize  the  active  metabolite.  Blood  samples  were
entrifuged  at  4 ◦C  within  30  minutes  and  stored  at
80 ◦C  until  assay.  Clopidogrel,  clopidogrel  carboxylic
cid,  clopidogrel  active  metabolite,  omeprazole,  5-
ydroxyomeprazole,  rabeprazole  and  rabeprazole  thioether
ere  extracted  from  plasma  on  a  solid  phase  OASIS
LB  cartridge  (10  mg/1  mL;  Waters  SAS,  Milford,  MA,
SA).  Chromatographic  separation  and  detection  of
ll  compounds  was  performed  on  a  YMC—UltraHT  Pro
18  analytical  column  (YMC,  Dinslaken,  Germany),
sing  ultra-high-performance  liquid  chromatography
oupled  to  a  tandem  mass  spectrometry  system  (UPLC-
cquity-TQD;  Waters  SAS,  Milford,  MA,  USA).  Limits
f  quantiﬁcation  were  0.1  ng/mL  for  clopidogrel  and
lopidogrel  active  metabolite,  5  ng/mL  for  rabeprazole
nd  rabeprazole  thioether,  10  ng/mL  for  clopidogrel
arboxylic  acid  and  50  ng/mL  for  omeprazole  and
-hydroxyomeprazole.
Pharmacokinetic  variable  values  were  calculated  using
inNonlin® Professional,  version  5.2  or  higher  (Pharsight
orp.,  Mountain  View,  CA,  USA).  The  maximum  plasma
oncentration  (Cmax)  and  the  time  of  its  occurrence  (Tmax)
ere  obtained  from  observed  values.  The  area  under  the
oncentration-time  curve  (AUC)  in  the  sampled  matrix  dur-
ng  a  dosing  interval  was  calculated  by  linear  up/log  down
rapezoidal  summation.  The  apparent  terminal  rate  cons-
ant  (z)  after  multiple  dosing  (1/hour),  was  determined
y  linear  regression  of  the  terminal  points  of  the  log-
inear  concentration-time  curve.  The  apparent  terminal
alf-life  after  multiple  dosing  (hours)  was  determined  as
ln2/z).
YP2C19 genotyping and activity
he  loss-of-function  CYP2C19  variants  *2  (rs4244285)  and
3  (rs4986893)  were  tested  using  polymerase  chain  reac-
ion  (PCR)-based  speciﬁc  probe  hybridization  and  single
ase  extension.  681G>A  and  636G>A  comprise  the  two  com-
on  reduced  functional  variants  CYP2C19*2  and  CYP2C19*3,espectively.  Subjects  with  the  CYP2C19*1/*1  genotype  were
esignated  as  CYP2C19  extensive  metabolizer  (EM)  subjects.
The  molar  omeprazole/5-hydroxyomeprazole  metabolic
atio  in  plasma  samples  at  3  hours  was  calculated  as  an
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ndex  of  CYP2C19  activity  [34—36]. In  one  EM  subject,
his  ratio  was  calculated  from  the  blood  sample  taken  at
 hours  because  5-hydroxyomeprazole  was  not  detectable
t  3  hours.
tatistical analyses
ample  size  was  calculated  with  the  assumption  that
pproximately  66%  of  subjects  would  be  good  antiplatelet
esponders,  deﬁned  as  subjects  in  whom  the  VASP  index
n  study  day  7  relative  to  study  day  1  would  decrease
y  ≥  30%,  with  an  expected  intrasubject  standard  devi-
tion  of  differences  in  PRI  of  ≤  14%  [37]  or  a  PRI
alue  at  day  7  below  a  cut-off  value  of  60%,  as  recently
roposed  for  clopidogrel  75  mg  daily  maintenance  dose
38]. With  these  assumptions,  36  subjects  are  sufﬁcient  to
onclude  non-inferiority  of  rabeprazole  to  placebo  with
0%  PRI  as  the  limit  of  non-inferiority  with  >  95%  power
hen  true  difference  in  treatment  means  is  equal  to  2%.
harmacodynamic  analyses  were  ﬁrst  performed  on  good
ntiplatelet  responders  as  deﬁned  above,  then  on  all  36
ubjects.
Mixed-effect  models  were  ﬁtted  to  the  PRI%  data  as  the
ependent  variable,  with  sequence,  treatment  and  period  as
actors  and  subject  as  a  random  effect.  Ninety  percent  conﬁ-
ence  intervals  (CIs)  were  calculated  for  the  difference  in
eans  between  rabeprazole  versus  placebo.  Non-inferiority
as  concluded  if  the  upper  limit  of  the  90%  CI  fell  below
0%.  This  non-inferiority  limit  was  chosen  because  it  rep-
esents  the  difference  between  omeprazole  and  placebo
eported  by  Gilard  et  al.  [21]  (10.7%  in  absolute  value,
3.4%  in  relative  value),  which  prompted  the  US  Food  and
rug  Administration’s  warning  on  the  interaction  of  PPIs  with
lopidogrel.
Additional  post-hoc  analyses  were  performed  to  compare
he  change  in  VASP  index  on  study  day  7  relative  to  study
ay  1  with  omeprazole  and  rabeprazole  relative  to  placebo,
sing  the  Wilcoxon  signed-rank  test  in  good  antiplatelet
esponders.  Post-hoc  correlation  analyses  were  performed
sing  Pearson’s  correlation.
A linear  mixed-effects  model  suitable  for  three-
ay  crossover  design  was  ﬁtted  to  log-transformed
harmacokinetic  variables,  and  90%  CIs  for  the  ratio
f  the  mean  pharmacokinetic  variables  of  clopido-
rel  were  constructed  using  least-square  means  and
ntrasubject  variance  from  the  model.  The  above  anal-
sis  was  performed  for  clopidogrel  active  metabo-
ite  and  clopidogrel  major  carboxylic  acid  metabolite.
ioequivalence  was  considered  as  demonstrated  if  the
0%  CIs  of  the  ratios  for  AUC0—24 and  Cmax between
he  placebo  and  PPI  study  periods  fell  in  the  range
0—125%.
esults
hirty-six  subjects  completed  the  three  study  periods.  Mean
ge,  body  weight  and  body  mass  index  were  33.6  ±  7.9  years,
24.1  ±  8.7  kg  and  23.6  ±  2.3  kg/m ,  respectively.  Of  these
6  subjects,  23  were  CYP2C19*1/*1  EMs,  12  were  heterozy-
ous  CYP2C19*1/*2  and  one  was  a  poor  metabolizer  with  the
YP2C19*2/*2  genotype.
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Figure 1. Change in vasodilator-stimulated phosphoprotein
(VASP) platelet reactivity index (PRI) at trough on day 7 of clopi-
dogrel 75 mg/day in the presence of placebo in 36 healthy subjects.
Figure 2. Change in vasodilator-stimulated phosphoprotein
platelet reactivity index (PRI) at trough on day 7 of clopidogrel
75 mg/day during co-administration of rabeprazole and omepra-
zole in 18 good antiplatelet responders. Each box plot represents
the interquartile range with mean (horizontal line in the box) and
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tSubjects in whom the VASP index on day 7 relative to day 1 was
decreased by ≥ 30% were deﬁned as good antiplatelet responders.
Platelet function assays
Baseline  VASP  index  before  administration  of  clopidogrel  was
not  signiﬁcantly  different  across  study  periods  (P  =  0.60).  As
expected,  there  was  considerable  interindividual  variability
in  platelet  function  inhibition,  as  measured  by  use  of  the
VASP  index  (VASP  PRI%)  on  day  7  of  the  clopidogrel  plus
placebo  study  period  prior  to  last  drug  administration  (D7H0)
(Fig.  1).  The  decrease  in  VASP  index  was  <  30%  in  18  subjects
while  the  other  18  subjects  were  classiﬁed  as  good  clopido-
grel  responders  (change  of  VASP  index  ≥  30%).  Table  1  shows
the  results  of  platelet  aggregation  studies  on  day  7  (D7)  of
each  study  period  before  (H0)  and  4  hours  after  (H4)  adminis-
tration  of  the  last  dose  of  clopidogrel  together  with  placebo,
omeprazole  and  rabeprazole.
In good  clopidogrel  responders  (as  evaluated  by  VASP
assay),  the  upper  limit  of  the  90%  CI  non-inferiority  thresh-
old  of  10%  was  crossed  during  co-prescription  of  omeprazole
but  not  during  co-prescription  of  rabeprazole  at  D7H0  and
D7H4.  Therefore,  in  this  predeﬁned  group  of  subjects  in
whom  signiﬁcant  antiplatelet  activity  was  present  during
administration  of  clopidogrel  with  placebo,  the  antiplatelet
effect  of  clopidogrel  during  co-administration  of  rabepra-
zole  was  non-inferior  to  placebo,  whereas  this  was  not  the
case  during  omeprazole  co-administration.  In  this  group,  the
increase  in  VASP  reactivity  index  relative  to  placebo  did  not
differ  signiﬁcantly  during  rabeprazole  and  omeprazole  co-
administration  (P  =  0.067;  Fig.  2).  However,  the  change  in
VASP  index  from  placebo  was  statistically  signiﬁcant  dur-
ing  omeprazole  (P  =  0.017)  but  not  rabeprazole  (P  =  0.26)
co-administration  at  D7H0  and  D7H4  (P  <  0.009  and  P =  0.20,
respectively)  (Table  1)
When  considering  the  entire  population  of  36  subjects,
the  VASP  index  at  D7H0  and  D7H4  was  not  signiﬁcantly
p
median (dot in the box); the whiskers represent the 5—95 per-
entiles. P = 0.067.
ltered  by  co-administration  of  omeprazole  or  rabeprazole.
he  increase  of  VASP  index  at  D7H4  with  omeprazole  did
ot  reach  statistical  signiﬁcance  (P  =  0.056).  Between-period
ifferences  were  less  consistent  when  considering  inhibition
f  platelet  aggregation  (IPA%)  induced  by  ADP  (Table  1).  The
0%  non-inferiority  threshold  was  crossed  in  all  subjects  for
oth  omeprazole  and  rabeprazole  only  in  the  presence  of
DP  10  M.
CYP2C19  genotype  inﬂuenced  the  antiplatelet  effects  of
lopidogrel.  Compared  with  subjects  with  the  CYP2C19*1/*2
enotype  (n  =  12),  EM  subjects  (n  =  23)  had  more  antiplatelet
ffects,  as  assessed  by  the  change  in  VASP  index  at
7H0  during  placebo  co-administration  (—39.3  ±  0.20%  in
YP2C19*1/*1  vs.  —22  ±  0.15%  in  CYP2C19*1/*2; P  <  0.015).
mong  the  23  EM  subjects,  15  were  good  antiplatelet
esponders.  One  subject  became  a  non-responder  with
meprazole;  none  became  non-responders  with  rabepra-
ole  (Fig.  3).  Among  the  12  subjects  with  the  CYP2C19*1/*2
enotype,  only  three  were  good  antiplatelet  responders  dur-
ng  administration  of  clopidogrel  with  placebo.  One  subject
ecame  a non-responder  with  both  rabeprazole  and  omepra-
ole  (Fig.  3).
lopidogrel disposition kinetics
able  2 shows  the  main  pharmacokinetic  variables  for  clopi-
ogrel  active  metabolite  in  all  subjects.  We  also  analysed
harmacokinetics  variables  in  EM  subjects  homozygous  for
YP2C19*1*1.  Fig.  4  shows  the  plasma  concentration  versus
ime  proﬁle  of  clopidogrel  active  metabolite  in  all  subjects.In  the  entire  population,  despite  a  signiﬁcant  fall  com-
ared  with  placebo,  the  AUC0—24 of  clopidogrel  active
etabolite  during  rabeprazole  co-administration  remained
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Table  1  Antiplatelet  effects  of  clopidogrel  75  mg/day  for  7  days  in  the  presence  of  placebo,  omeprazole  and  rabeprazole.
Treatment  n  Least  square  Pairwise  comparisons
Mean  (%)  95%  CI  Pair  Difference  (%)  90%  CI  Pa
VASP  PRI  (%)
Good  VASP  antiplatelet
respondersb
Day  7/hour  0  RABE  18  —47.3  (—52.5;  —42.1)  RABE/OME  —4.1  (—9.2;  1.0)  0.18
RABE/PLBO  3.4  (—1.7;  8.5)  0.26
OME  18  —43.2  (—48.4;  —38.0)  OME/PLBO  7.5  (2.5;  12.6)  0.017
PBO  18  —50.7  (—55.9;  —45.6)
Day  7/hour  4  RABE  18  —56.2  (—62.5;  —49.9)  RABE/OME  —4.9  (—10.5;  —0.8)  0.15
RABE/PLBO  4.4  (—1.2;  9.9)  0.2
OME  18  —51.3  (—57.6;  —45.1)  OME/PLBO  9.2  (3.6;  14.8)  0.0087
PBO  18  —60.3  (—66.8;  —54.3)
All  subjects
Day  7/hour  0  RABE  36  —32.1  (—38.8;  —25.5)  RABE/OME  —1.6  (—5.1;  1.8)  0.44
RABE/PLBO  0.4  (—3.1;  3.8)  0.85
OME  36  —30.5  (—37.5;  —23.9)  OME/PLBO  2  (—1.5;  5.5)  0.34
PBO  36  —32.5  (—39.2;  —25.9)
Day  7/hour  4  RABE  36  —39.8  (—47.4;  —32.1)  RABE/OME  —3.7  (—7.2;  —0.1)  0.089
RABE/PLBO  0.5  (—3.1;  4.0)  0.82
OME  36  —36.1  (—43.8;  —28.5)  OME/PLBO  4.2  (0.6;  7.7)  0.056
PBO  36  —40.3  (—47.9;  —32.6)
Inhibition  of  platelet
aggregation  induced  by
ADP  day  7/hour  0
All  subjects
ADP  20  M  RABE  36  39.4  (32.4;  46.4)  RABE/OME  4.3  (—0.1;  8.8)  0.11
RABE/PLBO  —0.8  (-5.3;  3.7)  0.77
OME  36  35.1  (28.1;  42.1)  OME/PLBO  —5.1  (—9.6;  —0.6)  0.063
PBO  35  40.2  (33.1;  47.2)
ADP  10  M  RABE  36  39.8  (32.7;  46.9)  RABE/OME  0.6  (—4.7;  5.8)  0.86
RABE/PLBO  —6.3  (—11.6;  —1.1)  <  0.05
OME  36  39.2  (32.1;  46.3)  OME/PLBO  —6.9  (—12.2;  —1.6)  0.033
PBO  35  46.1  (39.0;  53.3)
ADP: adenosine diphosphate; CI: conﬁdence interval; IPA: inhibition of platelet aggregation; OME: omeprazole; PLBO: placebo; PRI: change in platelet reactivity index; RABE: rabeprazole;
VASP: vasodilator-stimulated phosphoprotein.
a P values for equality of means.
b Good antiplatelet responders were deﬁned as subjects in whom the VASP index on day 7 relative to day 1 was decreased by ≥ 30%.
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Table  2  Pharmacokinetics  of  clopidogrel  active  metabolite  on  day  7 of  clopidogrel  75  mg/day  in  the  presence  of  placebo,
omeprazole  and  rabeprazole.
Treatment  n  Geometric  least  square  Pairwise  comparisons
Mean  95%  CI  Pair  Ratio  (%)  90%  CI  P
All  subjects
AUC0—24 (ng*hours/mL)  RABE  36  26.6  (23.1;  30.6)  RABE/OME  108.1  (100.0;  116.9)  0.10
RABE/PLBO  88.4  (81.7;  95.6)  0.01
OME  36  24.6  (21.4;  28.3)  OME/PLBO  81.7  (75.6;  88.4)  < 0.0001
PLBO  36  30.1  (26.2;  34.6)
Cmax (ng/mL)  RABE  36  15.1  (12.5;  18.1)  RABE/OME  105.8  (90.6;  123.6)  0.54
RABE/PLBO  72.1  (61.7;  84.2)  < 0.001
OME  36  14.3  (11.9;  17.1)  OME/PLBO  68.1  (58.3;  79.5)  0.0001
PLBO  36  20.9  (17.4;  25.2)
t½ (hours)  RABE  19  4.5  (2.7;  7.7)  RABE/OME  91.5  (56.8;  147.4)  0.75
RABE/PLBO  105.3  (65.3;  169.5)  0.86
OME  19  5.0  (2.9;  8.4)  OME/PLBO  115.0  (71.4;  185.3)  0.62
PLBO  19  4.3  (2.6;  7.3)
CYP2C19  *1/*1
AUC0—24 (ng*hours/mL)  RABE  23  29.8  (25.7;  34.5)  RABE/OME  107.1  (97.8;  117.3)  0.21
RABE/PLBO  82.3  (75.1;  90.2)  0.0009
OME  23  27.8  (24.0;  32.2)  OME/PLBO  76.8  (70.1;  84.2)  < 0.0001
PLBO  23  36.2  (31.3;  41.9)
Cmax (ng/mL)  RABE  23  16.7  (13.3;  21.1)  RABE/OME  104.1  (86.6;  125.3)  0.72
RABE/PLBO  66.8  (55.4;  80.5)  0.0008
OME  23  16.1  (12.8;  20.3)  OME/PLBO  64.1  (53.3;  77.2)  0.0002
PLBO  23  25.1  (19.9;  31.6)
t½ (hours)  RABE  10  6.4  (3.3;  12.6)  RABE/OME  126.5  (62.5;  256.1)  0.57
RABE/PLBO  75.8  (37.0;  155.4)  0.51
OME  10  5.1  (2.5;  10.1)  OME/PLBO  59.9  (28.1;  127.5)  0.25
PLBO  10  8.5  (4.2;  17.0)
AUC0—24: area under plasma concentration-time curve from 0 to 24 hours; CI: conﬁdence interval; Cmax: maximum observed plasma
concentration; t : apparent elimination half-life; OME: omeprazole; PLBO: placebo; RABE: rabeprazole.
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within  the  bioequivalence  limits  relative  to  the  placebo
study  period.  This  was  not  the  case  during  omeprazole  co-
administration.  Bioequivalence  was  not  met  for  Cmax during
administration  of  both  PPIs.  In  EM  subjects,  bioequivalence
was  not  met  for  any  of  the  measured  variables  during  both
omeprazole  and  rabeprazole  co-administration.  Mean  Tmax
was  0.67  hours  in  the  three  study  groups.
The  AUC0—24 and  apparent  elimination  half-life  of  clopi-
dogrel  and  its  main  carboxylic  acid  metabolite  remained
within  the  bioequivalence  range  during  both  omeprazole
and  rabeprazole  co-administration  (data  not  shown).  Other
variables  that  were  not  bioequivalent  were:  Cmax of  clopido-
grel  during  the  rabeprazole  study  period  (ratio  of  85.1,  90%
CI  75.1—98.0);  and  Cmax of  carboxylic  acid  metabolite  during
rabeprazole  (ratio  of  82.0,  90%  CI  72.2—93.2)  and  omepra-
zole  (ratio  of  83.3,  90%  CI:  73.3—94.6)  co-administration.
In  the  23  subjects  who  were  CYP2C19  EMs,  AUC0—24 of
clopidogrel  active  metabolite  decreased  signiﬁcantly  during
co-administration  of  omeprazole  and  rabeprazole  (Fig.  5).Regression analyses
Platelet  reactivity  (VASP  PRI)  at  D7H0  correlated  nega-
tively  with  clopidogrel  active  metabolite  AUC0—24 during
m
c
6lacebo  (r2 =  0.32;  n  =  36;  P  <  0.001),  rabeprazole  (r2 =  0.30;
 =  36;  P  <  0.001)  and  omeprazole  (r2 =  0.18;  n =  36;  P  < 0.007)
o-administration.  The  change  in  VASP  PRI  at  D7H0
rom  placebo  during  each  PPI  study  period  correlated
ositively  with  the  change  in  clopidogrel  active  metabo-
ite  AUC0—24 during  co-administration  of  the  corresponding
rug:  rabeprazole  (r2 =  0.11;  n  =  36;  P  < 0.025)  or  omeprazole
r2 =  0.11;  n  =  36;  P  <  0.027).
The  omeprazole  metabolic  ratio  could  not  be  determined
n  one  EM  subject.  The  change  in  platelet  inhibition  (VASP
PRI)  at  D7H0  during  the  placebo  period  and  the  change
n  platelet  aggregation  (IPA%)  induced  by  ADP  10  M  (but
ot  20  M)  at  D7H0  correlated  positively  with  the  omepra-
ole  metabolic  ratio  (r2 =  0.19;  n  =  35;  P  <  0.006  and  r2 =  0.17;
 =  35;  P  <  0.009,  respectively),  a  higher  metabolic  ratio  (i.e.
ess  CYP2C19  activity)  being  associated  with  less  antiplatelet
ffect.  No  signiﬁcant  correlation  was  found  between  the
hange  in  VASP  index  or  the  change  in  the  AUC  for  clopidogrel
ctive  metabolite  during  omeprazole  or  rabeprazole  periods
nd  CYP2C19  activity  as  assessed  by  use  of  the  omeprazole
etabolic  ratio.
There  was  no  correlation  between  omeprazole  plasma
oncentration  at  3  hours  (mean  ±  standard  deviation:
65  ±  576  ng/mL),  or  rabeprazole  (351  ±  233  ng/mL)  or
668  
Figure 3. Change in vasodilator-stimulated phosphoprotein
platelet reactivity index (PRI) at trough on day 7 of clopidogrel
75 mg/day in the presence of placebo, rabeprazole and omepra-
zole in 36 healthy subjects, according to CYP2C19 genotypes. CYP:
cytochrome P450.
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Figure 4. Mean (standard deviation) plasma concentration of clopidog
75 mg/day in the presence of placebo, rabeprazole and omeprazole in 3C.  Funck-Brentano  et  al.
abeprazole  thioether  (129  ±  85  ng/mL)  plasma  concentra-
ion  at  4  hours,  and  the  change  in  VASP  PRI  during  the
orresponding  PPI  combination  therapy.
The  falls  in  clopidogrel  active  metabolite  Cmax
nd  AUC0—24 during  rabeprazole  and  omeprazole  co-
dministration  were  correlated  (r2 =  0.56;  n  =  36;  P  < 0.001
n  both  cases)  and  the  slopes  of  these  relationships  did  not
iffer  signiﬁcantly  from  unity.
iscussion
his  randomized  crossover  study  was  designed  to  analyse
he  potential  interaction  between  clopidogrel  and  rabepra-
ole,  omeprazole  being  used  as  a  putative  positive  control.
t  was  conducted  in  healthy  male  volunteers,  thus  elim-
nating  potential  confounding  factors,  including  smoking,
on-compliance  and  other  medications.
As  an  inhibitory  interaction  is  not  expected  to  occur
n  subjects  who  do  not  have  an  adequate  response  in
he  absence  of  inhibitor,  the  predeﬁned  group  of  VASP
ood  antiplatelet  responders  was  chosen  to  examine  the
harmacodynamic  interactions  between  rabeprazole  and
lopidogrel.  The  VASP  index  is  considered  as  a  speciﬁc
est  for  evaluating  P2Y12  inhibition,  while  light-transmission
ggregometry  is  used  to  predict  outcome  during  dual
rel active metabolite as a function of time on day 7 of clopidogrel
6 healthy subjects.
PK/PD  interaction  between  rabeprazole  and  clopidogrel  
Figure 5. Area under the plasma concentration-time curve from 0
to 24 hours for clopidogrel active metabolite on day 7 of clopidogrel
75 mg/day in the presence of placebo, rabeprazole and omepra-
zole in 36 healthy subjects, according to CYP2C19 genotypes. CYP:
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patients  with  ischaemic  heart  disease  who  usually  receivecytochrome P450; NS: not signiﬁcant. * P < 0.001.
antiplatelet  therapy,  although  both  tests  have  a  predictive
value  [31,33,39,40].  In  the  group  of  good  VASP  antiplatelet
responders,  the  clopidogrel  antiplatelet  effect  remained
non-inferior  to  placebo  at  D7H0  and  D7H4  during  rabeprazole
co-administration,  whereas  it  crossed  the  limit  of  non-
inferiority  during  omeprazole  co-administration.  Therefore,
from  a  pharmacodynamic  point  of  view,  in  subjects  in  whom
clopidogrel  elicits  a  marked  antiplatelet  effect,  inhibition  of
clopidogrel  antiplatelet  action  is  minimal  with  rabeprazole,
whereas  a  statistically  signiﬁcant  reversal  of  clopidogrel
effects  is  observed  with  omeprazole.
However,  when  using  aggregometry  —  a  test  less  speciﬁc
for  P2Y12  but  that  reﬂects  the  global  platelet  function  —
inhibition  of  platelet  aggregation  induced  by  ADP  10  M
signiﬁcantly  decreased  with  both  omeprazole  and  rabepra-
zole  in  the  entire  population.  These  results  are  in  line
with  pharmacokinetic  analysis,  showing  a  decreased  expo-
sure  to  clopidogrel  active  metabolite  with  both  PPIs.  The
AUC0—24 and  Cmax of  clopidogrel  active  metabolite  signiﬁ-
cantly  decreased  with  both  omeprazole  and  rabeprazole,
and  conditions  of  bioequivalence  were  not  met,  except  for
AUC0—24 with  rabeprazole.  This  discrepancy  between  phar-
macokinetic  and  pharmacodynamic  variable  (VASP)  changes
was  also  found  in  a  drug  interaction  study  that  examined
the  inﬂuence  of  pantoprazole  (80  mg/day)  on  clopidogrel
antiplatelet  effects  and  exposure  to  its  active  metabolite
[19].  In  this  study,  no  signiﬁcant  change  in  VASP  index  (but
signiﬁcant  changes  in  ADP  5  M-induced  maximum  platelet
aggregation)  was  found  despite  a  statistically  signiﬁcant
decrease  in  clopidogrel  active  metabolite  AUC0—24 and  Cmax
with  pantoprazole,  of  the  same  order  of  magnitude  as
that  found  in  our  study.  Greater  decreases  in  exposure  to
d
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lopidogrel  active  metabolite  were  found  with  high-dose
meprazole  (80  mg/day)  in  a  study  by  Angiollilo  et  al.  [19]
nd  were  associated  with  signiﬁcant  inhibition  of  VASP  and
DP-induced  platelet  aggregation.  In  our  study,  the  change
n  VASP  index  with  PPIs  was  weakly  associated  (r2 =  0.11)
ith  the  change  in  exposure  to  clopidogrel  active  metabo-
ite  produced  by  omeprazole  and  rabeprazole,  although
he  association  between  VASP  index  and  clopidogrel  active
etabolite  AUC0—24 was  stronger  (r2 =  0.32)  during  adminis-
ration  of  clopidogrel  with  placebo.  Taken  together,  these
esults  suggest  that  a  certain  extent  of  pharmacokinetic
nteraction  with  clopidogrel  active  metabolite  is  necessary
o  produce  a  signiﬁcant  pharmacodynamic  interaction;  this
ould  explain  why  the  amplitude  of  the  pharmacodynamic
nteraction  we  found  with  omeprazole  was  limited  in  size.
As  expected  [22,23],  CYP2C19  genotype  and  activity
nﬂuenced  clopidogrel  antiplatelet  activity  in  the  absence
f  PPI,  with  greater  inhibition  of  platelet  aggregation  in
omozygous  EM  subjects  compared  with  subjects  with  at
east  one  non-functional  CYP2C19  allele.  Also,  during  the
lacebo  study  period,  clopidogrel-induced  change  in  VASP
ndex  and  platelet  aggregation  induced  by  10  M  (but  not
0  M)  ADP  correlated  with  CYP2C19  activity,  as  assessed  by
he  use  of  the  omeprazole  metabolic  ratio.  However,  the
ssociation  was  weak,  with  only  about  18%  of  antiplatelet
ffect  explained  by  the  omeprazole  metabolic  ratio.  Dur-
ng  PPI  administrations,  no  signiﬁcant  correlation  was  found
etween  the  change  in  VASP  index  or  the  change  in  the
UC  of  clopidogrel  active  metabolite  and  CYP2C19  activ-
ty  as  assessed  by  the  omeprazole  metabolic  ratio.  Such
n  absence  of  association  by  regression  analysis  raises  the
uestion  of  the  role  of  CYP2C19  inhibition  in  explaining
ur  ﬁndings.  Rabeprazole  is  mainly  metabolized  by  non-
nzymatic  reduction  to  rabeprazole  thioether  [41]  and
s  a  less  potent  inhibitor  of  CYP2C19  than  omeprazole
14,42,43].  This  may  explain  why  rabeprazole  had  less  effect
han  omeprazole  on  the  clopidogrel-induced  change  in  VASP
ndex,  although  the  study  was  not  powered  to  test  the  sta-
istical  signiﬁcance  of  this  difference.  However,  this  does
ot  explain  the  similarity  of  the  pharmacokinetic  interac-
ion  of  clopidogrel  active  metabolite  with  both  PPIs.  In  this
espect,  pantoprazole  [19]  and  rabeprazole  appear  to  have
imilar  proﬁles.  Also,  rabeprazole  thioether,  the  main  cir-
ulating  metabolite  of  rabeprazole,  is  a  CYP2C19  inhibitor
14]  and  could  have  contributed  to  the  observed  effects.
inally,  CYP2C19  is  not  the  only  CYP  that  contributes  to
he  bioactivation  of  clopidogrel  to  its  active  metabolite
4]. CYP2C19  contributes  to  the  ﬁrst  step  of  clopidogrel
etabolism  to  its  2-oxo  unstable  metabolite  by  45%  while
YP1A2  and  CYP2B6  contribute  by  36%  and  19%,  respec-
ively.  CYP2C19  contributes  to  the  ﬁnal  step  of  clopidogrel
ctive  metabolite  formation  from  2-oxoclopidogrel  by  only
0%  while  CYP3A4,  CYP2B6  and  CYP2C9  contribute  by  40%,
3%  and  7%,  respectively  [4].  It  is  therefore  conceivable  that
on-CYP2C19-mediated  mechanisms  may  contribute  to  the
nteraction  between  PPIs  and  clopidogrel.
For  uniformity,  our  study  included  only  young  male  vol-
nteers,  a  population  that  does  not  reﬂect  the  diversity  ofual  antiplatelet  therapy  and  an  initial  loading  dose  of
lopidogrel.  In  the  target  population,  clopidogrel  is  usu-
lly  prescribed  with  aspirin,  and  it  has  been  suggested  that
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nhibition  of  antiplatelet  effect  may  result  from  an  inter-
ction  of  PPIs  with  aspirin  absorption  [44,45],  independent
f  the  interaction  with  clopidogrel  [46,47].  Inhibition  of
lopidogrel  absorption  by  PPIs  is  unlikely  to  occur  because
lopidogrel  is  a  weak  base  that  is  not  absorbed  from  the
tomach,  unlike  aspirin.  To  our  knowledge,  only  one  study
as  compared  the  effects  of  omeprazole  and  rabeprazole
n  the  antiplatelet  action  of  clopidogrel  in  patients  on  dual
ntiplatelet  therapy  [48].  In  this  open-label  study  in  a  lim-
ted  number  of  patients,  both  omeprazole  and  rabeprazole
educed  the  effects  of  clopidogrel  on  platelet  aggregation
nduced  by  10  M  ADP.  However,  the  authors  acknowledged
hat  their  study  was  not  placebo  controlled  and  did  not
ave  the  power  to  detect  a  difference  between  omepra-
ole  and  rabeprazole.  Another  recent  study  reported  on  the
nteraction  between  a  single  300  mg  dose  of  clopidogrel  and
abeprazole  (20  mg)  and  did  not  ﬁnd  an  interaction  [49].
onclusions
ur  study,  despite  the  limitations  indicated  above,  suggests
hat  the  interaction  between  rabeprazole  and  clopidogrel  is
ikely  to  be  less  pronounced  than  the  interaction  between
meprazole  and  clopidogrel  in  patients  with  heart  disease.
he  study  also  shows  that  the  interaction  with  omeprazole
s  of  small  amplitude  when  the  standard  therapeutic  dose  of
0  mg/day  is  used.  Under  our  experimental  conditions  and
PIs  doses,  there  was  no  signiﬁcant  pharmacodynamic  inter-
ction  between  rabeprazole  or  omeprazole  and  clopidogrel,
espite  a  signiﬁcant  decrease  in  the  formation  of  clopidogrel
ctive  metabolite;  this  is  consistent  with  a  previous  study
ith  pantoprazole  [19]  and  suggests  that  there  is  a  threshold
f  decreased  clopidogrel  active  metabolite  formation  that
s  required  to  produce  a  pharmacodynamic  interaction.
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